GENMAB A/S (GMAB) Form 6-K — Oct 13, 2026
Genmab announced that worldwide net trade sales of DARZALEX (daratumumab) totaled USD 4,239 million in the third quarter of 2026, as reported by partner Johnson & Johnson. U.S. net trade sales were USD 2,528 million, with USD 1,711 million from the rest of the world, including the subcutaneous product DARZALEX FASPRO.
Key figures
- Revenue
- $4,239 million DARZALEX net sales Q3 2026 (as reported by J&J)
- Us net trade sales
- USD 2,528 million
- Rest of world net trade sales
- USD 1,711 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.